Ankylosing spondylitis is a relatively common chronic inflammatory disease in which genetic factors, particularly HLA-B27, play an important role in susceptibility. Treatment options were historically limited, but the advent of TNF-α blocker has revolutionized treatment and these drugs are now recommended as the only alternative for patients who fail to respond sufficiently to NSAID treatment. In this book of eight chapters, international experts come together to provide a topical overview of ankylosing spondylitis. The book opens with an overview of the history and pathophysiology and disease. There follow chapters on diagnosis and the various therapeutic options available and in development. The book includes a review of outcome measurement and concludes with a look at treatment algorithms and prognosis.